This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine if the Dose Limiting Toxicity (DLT) is reached in the dose escalation scheme described, using intradermal injections of autologous dendritic cells harvested from peripheral blood precursors and pulsed (co-cultured) with synthetic GAA peptides in patients with newly diagnosed or recurrent Grade III-IV malignant glioma. If DLT is reached, then Maximum tolerated Dose (MTD) will be defined.
Showing the most recent 10 out of 1085 publications